SEC Filing Summary: Renovaro, Inc. (RENB)
Business Context and Reporting Period
This Form 8-K, dated April 8, 2025, reports the consummation of a previously announced merger transaction by Renovaro, Inc. (the "Company"). The filing details the acquisition of Biosymetrics, Inc. ("Biosymetrics") through a merger with Renovaro Acquisition Sub, a wholly-owned subsidiary of Renovaro. Biosymetrics survives the transaction as a wholly-owned subsidiary of Renovaro.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the Company or the acquired entity. The primary financial metric disclosed is the issuance of 15.0 million shares of Renovaro common stock (par value $0.0001) to former Biosymetrics stockholders as consideration for the transaction.
Material Changes
- Transaction Completion: The merger agreement entered into on February 26, 2025, was consummated on April 8, 2025.
- Capital Structure: The Company's outstanding share count increased by 15.0 million shares issued to Biosymetrics shareholders.
- Ownership Structure: Biosymetrics is now a wholly-owned subsidiary of Renovaro.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future performance, or specific risk factors beyond the standard disclosure of the transaction mechanics. The issuance of shares was conducted in reliance on the Section 4(a)(2) exemption from registration under the Securities Act of 1933, based on representations that all recipients were accredited investors.
Investor Verification Checklist
- Verify the exact number of shares issued (15.0 million) and the resulting dilution impact on existing shareholders.
- Confirm the post-transaction capitalization table and ownership percentages.
- Review the original Merger Agreement (referenced in prior filings) for details on earn-outs, contingent consideration, or integration plans not detailed in this 8-K.
- Check for subsequent filings (e.g., 10-Q or 10-K) that will incorporate the financial results of Biosymetrics.